{"id":653565,"date":"2023-05-30T08:22:01","date_gmt":"2023-05-30T08:22:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=653565"},"modified":"2023-05-30T08:22:01","modified_gmt":"2023-05-30T08:22:01","slug":"pd1-nonsmall-cell-lung-cancer-pipeline-constitute-of-30-leading-companies-working-to-develop-30-pipeline-therapies-for-pd1-nonsmall-cell-lung-cancer-treatment-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/pd1-nonsmall-cell-lung-cancer-pipeline-constitute-of-30-leading-companies-working-to-develop-30-pipeline-therapies-for-pd1-nonsmall-cell-lung-cancer-treatment-delveinsight_653565.html","title":{"rendered":"PD-1 Non-Small Cell Lung Cancer pipeline constitute of 30+ leading companies working to develop 30+ pipeline therapies for PD-1 Non-Small Cell Lung Cancer treatment | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1685361743.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"PD-1 Non-Small Cell Lung Cancer pipeline constitute of 30+ leading companies working to develop 30+ pipeline therapies for PD-1 Non-Small Cell Lung Cancer treatment | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1685361743.jpeg\" alt=\"PD-1 Non-Small Cell Lung Cancer pipeline constitute of 30+ leading companies working to develop 30+ pipeline therapies for PD-1 Non-Small Cell Lung Cancer treatment | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>PD-1 Non-Small Cell Lung Cancer pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">(New York, USA) DelveInsight&rsquo;s, &ldquo;<strong>PD-1 Non-Small Cell Lung Cancer Pipeline Insights, 2023<\/strong>,&rdquo; report provides comprehensive insights about <strong>30+ companies<\/strong> and <strong>30+ pipeline drugs<\/strong> in the PD-1 Non-Small Cell Lung Cancer pipeline landscape. It covers the PD-1 Non-Small Cell Lung Cancer pipeline drug profiles, including PD-1 Non-Small Cell Lung Cancer clinical trials and nonclinical stage products. It also covers the PD-1 Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To explore more information on the latest breakthroughs in the PD-1 Non-Small Cell Lung Cancer Pipeline treatment landscape of the report, click here @&nbsp;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\"><strong>PD-1 Non-Small Cell Lung Cancer Pipeline Outlook<\/strong><\/a>&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key takeaways from the PD-1 Non-Small Cell Lung Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Over 30+ PD-1 Non-Small Cell Lung cancer companies are evaluating 30+ PD-1 Non-Small Cell Lung Cancer pipeline therapies in various stages of development, and their anticipated acceptance in the PD-1 Non-Small Cell Lung Cancer market would significantly increase market revenue.<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>The leading PD-1 Non-Small Cell Lung Cancer Companies include Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Bristol Myers Squibb, Sanofi, IO Biotech, Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, and others.<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>Promising PD-1 Non-Small Cell Lung Cancer Pipeline Therapies includes REGN2810, Chemotherapy, CV301, Pembrolizumab, Nivolumab, Cyclophosphamide, DV281, Breath Actuated Nebulizer, DV281 (RP2D), AK105, carboplatin, pemetrexed, Tislelizumab, Docetaxel, TSR-042 (Dostarlimab), MK-3475, and others.<\/li>\n<li>The PD-1 Non-Small Cell Lung Cancer companies and academics are working to assess challenges and seek opportunities that could influence PD-1 Non-Small Cell Lung Cancer R&amp;D. The PD-1 Non-Small Cell Lung Cancer pipeline therapies under development are focused on novel approaches to treat\/improve PD-1 Non-Small Cell Lung Cancer.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>PD-1 Non-Small Cell Lung Cancer Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. About 80% to 85% of lung cancers are Non-Small Cell Lung Cancer. The main subtypes of Non-Small Cell Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells are grouped together as Non-Small Cell Lung Cancer because their treatment and prognoses (outlook) are often similar.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Got Queries? Find out the related information on PD-1 Non-Small Cell Lung Cancer Mergers and acquisitions, PD-1 Non-Small Cell Lung Cancer Licensing Activities @&nbsp;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\"><strong>PD-1 Non-Small Cell Lung Cancer Emerging Drugs, and Recent Trends<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Latest Developmental Activities or News of PD-1 Non-Small Cell Lung Cancer Treatment Landscape<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>In February 2021, Arcus Biosciences initiated a Randomized Phase III Open-label Study will Evaluate the Efficacy of Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined withAB154 in Front-Line, PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Gilead and Arcus entered into a 10-year collaboration that provided Gilead immediate rights to zimberelimab and the right to opt into all other Arcus programs arising during the collaboration term.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>For further information, refer to the detailed PD-1 Non-Small Cell Lung Cancer Unmet Needs, PD-1 Non-Small Cell Lung Cancer Market Drivers, and PD-1 Non-Small Cell Lung Cancer Market Barriers, click here for&nbsp;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\"><strong>PD-1 Non-Small Cell Lung Cancer Clinical Trial Analysis<\/strong><\/a>&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>PD-1 Non-Small Cell Lung Cancer Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>REGN2810 (cemiplimab) plus Ipilimumab Combination Therapy (REGN2810\/ipi): Regeneron Pharmaceuticals \/ Sanofi<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">REGN2810 (SAR439684) is an antibody-based cancer therapy that Regeneron Pharmaceuticals is developing in collaboration with Sanofi. REGN2810 is a monoclonal antibody, or manmade copy of a protein that immune cells generate to fight invaders. It targets a protein called programmed cell death 1, or PD-1, on the surface of immune T-cells and precursor B-cells, or pro-B cells. Precursor B-cells are immature white blood cells that develop into fully formed B-cells. PD-1 suppresses the immune system by binding to programmed death-ligand 1, or PD-L1 &mdash; another cell surface protein that several cancers overproduce. By binding with PD-1, REGN 2810 blocks the interaction between PD-1 and PD-L1, promoting T-cell growth and survival. The result is a revved-up immune system that can then attack cancer cells.&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Tislelizumab (BGB-A317) &#8211; BeiGene<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Tislelizumab (BGB-A317) is a humanized IgG4 anti&ndash;PD-1 monoclonal antibody specifically designed to minimize binding to Fc&gamma;R on macrophages. In pre-clinical studies, binding to Fc&gamma;R on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug from BeiGene&rsquo;s immuno-oncology biologics program and is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>PD-1 Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">There are approx. 30+ key companies which are developing the therapies for PD-1 Non-Small Cell Lung Cancer. The companies which have their PD-1 Non-Small Cell Lung Cancer drug candidates in the advanced stage, i.e. pre-registration and phase III include, <em><strong>BeiGene, Regeneron Pharmaceuticals, Sanofi etc.<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request a sample and discover the recent advances in PD-1 Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis and Medications, click here @&nbsp;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\"><strong>PD-1 Non-Small Cell Lung Cancer Treatment Landscape<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the PD-1 Non-Small Cell Lung Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer Companies- Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Bristol Myers Squibb, Sanofi, IO Biotech, Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, and others.<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer Pipeline Therapies- REGN2810, Chemotherapy, CV301, Pembrolizumab, Nivolumab, Cyclophosphamide, DV281, Breath Actuated Nebulizer, DV281 (RP2D), AK105, carboplatin, pemetrexed, Tislelizumab, Docetaxel, TSR-042 (Dostarlimab), MK-3475, and others.<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer Pipeline Segmentation: Phases, Mechanism of Action, Route of Administration, Product Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dive deep into rich insights for drugs for PD-1 Non-Small Cell Lung Cancer Market Drivers and PD-1 Non-Small Cel&nbsp;Lung Cancer Market Barriers, click here @&nbsp;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\"><strong>PD-1 Non-Small Cell Lung Cancer Unmet Needs and Analyst Views<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer: Overview<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer Pipeline Therapeutics<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer Therapeutic Assessment<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer &ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>In-depth Commercial Assessment<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer Collaboration Deals<\/li>\n<li>Late Stage Products (Pre-registration)<\/li>\n<li>Tislelizumab: BeiGene<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>REGN2810\/ipi: Regeneron Pharmaceuticals \/ Sanofi<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>RG 7769: Roche<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>TQ B2450: Apollomics; Chia Tai Tianqing Pharmaceutical Group<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer Pre-clinical and Discovery Stage Products<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive PD-1 Non-Small Cell Lung Cancer Products<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer Companies<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer Key Products<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer- Unmet Needs<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer- Market Drivers and Barriers<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer- Future Perspectives and Conclusion<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer Analyst Views<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&amp;D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers &amp; Acquisitions.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=pd1-nonsmall-cell-lung-cancer-pipeline-constitute-of-30-leading-companies-working-to-develop-30-pipeline-therapies-for-pd1-nonsmall-cell-lung-cancer-treatment-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=pd1-nonsmall-cell-lung-cancer-pipeline-constitute-of-30-leading-companies-working-to-develop-30-pipeline-therapies-for-pd1-nonsmall-cell-lung-cancer-treatment-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PD-1 Non-Small Cell Lung Cancer pipeline (New York, USA) DelveInsight&rsquo;s, &ldquo;PD-1 Non-Small Cell Lung Cancer Pipeline Insights, 2023,&rdquo; report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the PD-1 Non-Small Cell Lung Cancer pipeline landscape. It covers &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/pd1-nonsmall-cell-lung-cancer-pipeline-constitute-of-30-leading-companies-working-to-develop-30-pipeline-therapies-for-pd1-nonsmall-cell-lung-cancer-treatment-delveinsight_653565.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-653565","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/653565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=653565"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/653565\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=653565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=653565"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=653565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}